Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

More PDE5 inhibitors in the Pfizer pipeline

Jan. 18, 1999

Combination of lovastatin and acipimox for type II diabetes and mixed dyslipidemia

Jan. 15, 1999

Amantadine reverses adverse effects of neuroleptic drugs on sexual function in males

Jan. 15, 1999

Amylin files IND for antidiabetes drug and reports on feasibility of alternative delivery routes

Jan. 15, 1999

Amylin gears up for regulatory filing of pramlintide and presents new clinical data

Jan. 15, 1999

Novel compounds developed at Roche for lipid disorders and fungal infections

Jan. 15, 1999

Traditional Chinese medicine shows potential as Rx for hypercholesterolemia

Jan. 14, 1999

TKT and Sumitomo collaborate to commercialize Fabry's disease treatment in Asia

Jan. 14, 1999

Extensive toxicity testing conducted on HMG-CoA reductase inhibitor

Jan. 14, 1999

Mechanism of hypoglycemic activity of YM-268 investigated further

Jan. 14, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 29, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Will Ovid’s golden age of KCC2 metamorph CNS?
BioWorld
The “deep dive” April 8 by Ovid Therapeutics Inc. into potassium-chloride co-transporter 2 (KCC2) research included company officials and independent experts in...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...